shop now
clinical laboratory standards institute logo

 

About CLSI

 

Share Your Comments on New and Revised Standard Documents

Help shape the standards that impact your day-to-day work.

To preserve the integrity of standards developed through the CLSI consensus process, we seek input from the public on our in-process drafts before they are approved for publication. Opening the dialogue to CLSI members and non-members alike, we encourage your involvement in the final shaping of our documents to ensure that all interested parties are given a voice.

General Information

Comments related to CLSI draft documents shall be made in writing using the comment table form and shall be submitted no later than the comment deadline indicated above. Comments, as well as requests for a copy of the document, should be submitted via e-mail to standard@clsi.org or by fax to 610.688.0700.

Documents for Review and Comment

MM23 (Proposed Draft)Molecular Diagnostic Methods for Solid Tumors (Nonhematological Neoplasms)

This document covers the current state of molecular diagnostic techniques intended for the characterization of solid tumors, and covers a range of clinical applications including diagnosis, prognosis, therapeutic response prediction for approved drugs and those still in clinical trials, as well as monitoring and presymptomatic and predisposition testing.

This draft document is available to the public for review and comment for 60 days (August 28 to October 27). This review and comment period helps ensure that consensus is achieved so that approved consensus documents can be distributed for use in the health care community. At the end of the 60-day review and comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. CLSI greatly appreciates your valuable feedback.

M52 (Proposed Draft)Verification of Microbial Identification and Antimicrobial Susceptibility Testing Systems

This guideline provides recommendations for verification of commercial US Food and Drug Administration–cleared microbial identification and antimicrobial susceptibility testing systems by clinical laboratory professionals to fulfill regulatory or quality assurance requirements for the use of these systems for diagnostic testing.

This draft document is available to the public for review and comment for 60 days (September 10 to November 10). This review and comment period helps ensure that consensus is achieved so that approved consensus documents can be distributed for use in the health care community. At the end of the 60-day review and comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. CLSI greatly appreciates your valuable feedback.

Please note draft CLSI documents are available only for the purposes of review and comment, and are not to be reproduced or circulated for any other reason. Draft documents have not completed the consensus review process, and therefore, shall not be used for any clinical purposes or to satisfy regulatory or accreditation requirements. They should not to be considered either final or published and may not be quoted or referenced.

 

Did You Know?

CLSI distributes more than
75,000 standards and guidelines per year, worldwide.

Login

Register | Lost your password?